(VIANEWS) – Shares of Xenetic Biosciences (NASDAQ: XBIO) rose 9.39% to $0.43 at 12:29 EST on Monday, after five successive sessions in a row of losses. NASDAQ is dropping 0.68% to $11,743.22, after five sequential sessions in a row of gains. This seems, as yet, a somewhat negative trend trading session today.
Xenetic Biosciences’s last close was $0.39, 68.64% below its 52-week high of $1.25.
About Xenetic Biosciences
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Earnings Per Share
As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-1.704.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 18.6%, now sitting on 1.55M for the twelve trailing months.
Volume
Today’s last reported volume for Xenetic Biosciences is 14718 which is 76.18% below its average volume of 61796.
Sales Growth
Xenetic Biosciences’s sales growth for the current quarter is negative 39.9%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Xenetic Biosciences’s stock is considered to be overbought (>=80).
More news about Xenetic Biosciences (XBIO).
